Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has issued notice of allowance (NoA) to Israel-based PROLOR Biotech's CTP platform patent application.
Subscribe to our email newsletter
CTP platform helps in extending the duration of activity of virtually all therapeutic proteins.
The clinical and preclinical studies demonstrate that CTP technology is safe and effective in extending the duration of all proteins tested to date.
The NoA covers CTP-modified compositions of therapeutic proteins, which also includes hormones, high affinity protein ligands, proteins that induce or regulate an immune response, proteins that are involved with autocrine and paracrine activities, and mimetics of these therapeutic proteins, as well as other types of proteins.
PROLOR president Shai Novik said allowance of this new patent is of great importance for PROLOR’s intellectual property portfolio, since it covers a wide array of therapeutic proteins and extends the patent protection around our CTP platform for many years.
"We are confident that our growing CTP patent portfolio will provide significant protection for both our compounds in development and our platform technology, and we believe it will serve as an important value driver for PROLOR in the future," Novik said.